Real-world data for the use of emicizumab in haemophilia A patients with inhibitors - First nationwide report from Korea
Haemophilia
.
2023 Jul;29(4):1163-1166.
doi: 10.1111/hae.14819.
Epub 2023 Jun 22.
Authors
Seung Min Hahn
1
2
,
Jung Woo Han
1
2
,
Jin Seok Kim
3
,
Ye Jee Shim
4
,
Soyon Kim
5
,
Hugh Chul Kim
5
,
Young Shil Park
6
,
Chuhl Joo Lyu
1
2
Affiliations
1
Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea.
2
Department of Pediatric Hematology-Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
3
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
4
Department of Pediatrics, Keimyung University School of Medicine, Keimyung University Dongsan Hospital, Daegu, South Korea.
5
Kim & Lee's Internal Medicine Clinic, Seoul, South Korea.
6
Department of Pediatrics, Kyung Hee University College of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
PMID:
37347590
DOI:
10.1111/hae.14819
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Bispecific* / therapeutic use
Hemophilia A* / drug therapy
Humans
Republic of Korea / epidemiology
Substances
Antibodies, Bispecific
emicizumab